HONG KONG – Pfizer Inc. said its FDA breakthrough-designated breast cancer drug, Ibrance (palbociclib), could have a significant impact in Asia, based on a subanalysis in Asian women from a phase III trial, showing that the combination of Ibrance and letrozole significantly extended progression-free survival (PFS) by more than 11 months compared with letrozole plus placebo.